![](https://www.aptitudehealth.com/wp-content/uploads/2021/09/Cancer-Cell-09-Mobile.jpg)
CASES Insights Into Breast Cancer Central 2020
Perspectives on current treatment practices in the central region of the US regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer. And insights on current treatment practice attitudes toward recently introduced and upcoming agents
![](https://www.aptitudehealth.com/wp-content/uploads/2020/04/Mark-D-Pegram-MD-Aptitude-Health-CASES-Breast-Cancer-2020.jpg)
Faculty Chair
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA, USA
REPORT SNAPSHOT
Insights on the following breast cancer therapies were obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A moderated virtual roundtable discussion focusing on treatment of metastatic breast cancer was held in May 2020
- Disease state and data presentations were developed in conjunction with Mark Pegram, MD, a medical expert from Stanford Women’s Cancer Center
- The group of advisors comprised 13 community oncologists from the central region of the USA
- Data collection was accomplished through use of audience response system questioning and moderated discussion